// App-Quantinova.ai

BSH19‐PO‐094 : Studying the molecular mechanisms of resistance to the irreversible, covalent BTK inhibitor, Tirabrutinib

Researchers

Presenter

  • R. Jackson

Principal Investigators

  • S. Jayne

  • H. Walter

  • C. Trethewey

  • M. Dyer

Medical Centers

  • Leicester Cancer Research Centre,University of Leicester,Leicester,United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Chronic Lymphocytic Leukemia

  • Mantle cell lymphoma

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • BCL2 like 11

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

  • Bruton tyrosine kinase

  • Phospholipase C-gamma-2

  • Cluster of Differentiation 5

  • C-X-C motif chemokine ligand 8

  • Tumor protein p53

Drug/Treatment

  • Tirabrutinib

  • Ibrutinib

  • TP53

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT02457598

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved